Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.50 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.50 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | ERN1 | O75460 | 10/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31568859 | 0.90 | ERN1 (0.55) | TYRTRIM24TRIM33ERN1 | |
| SCHEMBL31099574 | 0.88 | TYR (0.55) | TYRTRIM24TRIM33ERN1 | |
| SCHEMBL31081472 | 0.88 | TYR (0.55) | TYRTRIM24TRIM33ERN1 | |
| SCHEMBL5333100 | 0.85 | ERN1 (0.66) | MCL1ERN1 | |
| SCHEMBL30008990 | 0.84 | TYR (0.52) | TYRTRIM24TRIM33ERN1 | |
| SCHEMBL28223614 | 0.84 | TYR (0.57) | TYRTRIM24TRIM33ERN1KDM4E | |
| SCHEMBL225766 | 0.84 | TYR (0.57) | TYRTRIM24TRIM33ERN1KDM4E | |
| SCHEMBL29953108 | 0.84 | TYR (0.57) | TYRTRIM24TRIM33ERN1KDM4E | |
| SCHEMBL5737950 | 0.83 | MCL1 (0.50) | TYRTRIM24TRIM33MCL1ERN1 | |
| SCHEMBL3364194 | 0.82 | ERN1 (0.49) | TYRTRIM24TRIM33ERN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157398-B2 | Covalently fixed nonmetallocenes, process for preparing them and their use for the polymerization of olefins | CELANESE VENTURES GMBH (DE) | 2007-01-02 | — | — | US | disclosed |
| EP-1244446-B1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20050148461-A1 | Covalently fixed nonmetallocenes, process for preparing them and their use for the polymerization of olefins | CELANESE VENTURES GMBH (DE) | 2005-07-07 | — | — | US | disclosed |
| US-6872843-B2 | Non-metallocene compounds, method for the production thereof and use of the same for the polymerization of olefins | BASELL POLYOLEFINE GMBH (DE) | 2005-03-29 | — | — | US | disclosed |
| US-6858630-B2 | Naphthimidazole derivatives and their use as thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-22 | — | — | US | disclosed |
| US-20040023940-A1 | Non-metallocene compounds, method for the production thereof and use of the same for the polymerisation of olefins | EQUISTAR CHEMICALS, LP | 2004-02-05 | — | — | US | disclosed |
| US-20030083361-A1 | Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia | SMITHKLINE BEECHAM CORPORATION | 2003-05-01 | — | — | US | disclosed |
| EP-1244446-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1244446-A1 | THROMBOPOIETIN MIMETICS | SmithKline Beecham Corporation (US) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001039773-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083361-A1 | Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia | MPL, THPO, TPO | TYR 242/4885TRIM24 1668/4885TRIM33 1693/4885 |
| US-20040023940-A1 | Non-metallocene compounds, method for the production thereof and use of the same for the polymerisation of olefins | SOAT2, NOTUM, SOAT1 | TYR 2640/4885TRIM24 2304/4885TRIM33 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.